Literature DB >> 16459720

Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis.

B A Kallmann1, S Fackelmann, K V Toyka, P Rieckmann, K Reiners.   

Abstract

Evoked potentials (EP) have a role in making the diagnosis of multiple sclerosis (MS) but their implication for predicting the future disease course in MS is under debate. EP data of 94 MS patients examined at first presentation, and after five and ten years were retrospectively analysed. Patients were divided into two groups in relation to the prior duration of disease at the time point of first examination: group 1 patients (n=44) were first examined within two years after disease onset, and group 2 patients (n=50) at later time points. As primary measures sum scores were calculated for abnormalities of single and combined EP (visual (VEP), somatosensory (SEP), magnetic motor evoked potentials (MEP)). In patients examined early after disease onset (group 1), a significant predictive value for abnormal EP was found with MEP and SEP sum scores at first presentation correlating significantly with Expanded Disability Status Scale (EDSS) values after five years, while the VEP sum score was not. The cumulative number of abnormal MEP, SEP and VEP results also indicated higher degrees of disability (EDSS > or = 3.5) after five years. Combined pathological SEP and MEP findings at first presentation best predicted clinical disability (EDSS > or = 3.5) after five years (odds ratio 11.0). EP data and EDSS at first presentation were not significantly linked suggesting that EP abnormalities at least in part represented clinically silent lesions not mirrored by EDSS. For patients in later disease phases (group 2), no significant associations between EP data at first presentation and EDSS at five and ten years were detected. Together with clinical findings and MR imaging, combined EP data may help to identify patients at high risk of long-term clinical deterioration and guide decisions as to immunomodulatory treatment.

Entities:  

Mesh:

Year:  2006        PMID: 16459720     DOI: 10.1191/135248506ms1244oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  19 in total

Review 1.  Neurophysiological markers.

Authors:  Letizia Leocani; Giancarlo Comi
Journal:  Neurol Sci       Date:  2008-09       Impact factor: 3.307

2.  Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

Authors:  H Wiendl; K V Toyka; P Rieckmann; R Gold; H-P Hartung; R Hohlfeld
Journal:  J Neurol       Date:  2008-10-29       Impact factor: 4.849

3.  Prognostic value of multimodal evoked potentials in multiple sclerosis: the EP score.

Authors:  Paolo Invernizzi; Laura Bertolasi; Maria Rachele Bianchi; Marco Turatti; Alberto Gajofatto; Maria Donata Benedetti
Journal:  J Neurol       Date:  2011-04-09       Impact factor: 4.849

4.  Sensory evoked potentials to predict short-term progression of disability in multiple sclerosis.

Authors:  N Margaritella; L Mendozzi; M Garegnani; E Colicino; E Gilardi; L Deleonardis; F Tronci; L Pugnetti
Journal:  Neurol Sci       Date:  2011-11-27       Impact factor: 3.307

5.  [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].

Authors:  Peter Rieckmann
Journal:  Nervenarzt       Date:  2006-12       Impact factor: 1.214

6.  Inpatient Rehabilitation: Prediction of Changes in Sensorimotor Performance in Multiple Sclerosis: A Pilot Study.

Authors:  Philipp Gulde; Joachim Hermsdörfer; Peter Rieckmann
Journal:  J Clin Med       Date:  2021-05-18       Impact factor: 4.241

7.  Exploring the predictive value of the evoked potentials score in MS within an appropriate patient population: a hint for an early identification of benign MS?

Authors:  Nicolò Margaritella; Laura Mendozzi; Massimo Garegnani; Raffaello Nemni; Elena Colicino; Elisabetta Gilardi; Luigi Pugnetti
Journal:  BMC Neurol       Date:  2012-08-22       Impact factor: 2.474

8.  Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosis.

Authors:  Silvia Rossi; Valeria Studer; Caterina Motta; Giorgio Germani; Giulia Macchiarulo; Fabio Buttari; Raffaele Mancino; Maura Castelli; Valentina De Chiara; Sagit Weiss; Gianvito Martino; Roberto Furlan; Diego Centonze
Journal:  J Neuroinflammation       Date:  2014-02-18       Impact factor: 8.322

9.  Improved characterization of visual evoked potentials in multiple sclerosis by topographic analysis.

Authors:  Martin Hardmeier; Florian Hatz; Yvonne Naegelin; Darren Hight; Christian Schindler; Ludwig Kappos; Margitta Seeck; Christoph M Michel; Peter Fuhr
Journal:  Brain Topogr       Date:  2013-10-02       Impact factor: 3.020

Review 10.  Clinical, MRI, and CSF markers of disability progression in multiple sclerosis.

Authors:  Alberto Gajofatto; Massimiliano Calabrese; Maria Donata Benedetti; Salvatore Monaco
Journal:  Dis Markers       Date:  2013-11-10       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.